Of all the 11th hour attempts to finalize drug pricing policy changes by the outgoing Trump Administration, a final rule eliminating rebates in the US Medicare outpatient drug program (Part D) is both the easiest and most certain to be blocked by the new Biden Administration.
The rule is not popular with Democrats, who view it as essentially doing the drug industry’s bidding. That message was...






